Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468910 | 1.00 | ROCK1 (0.49) | ROCK1ROCK2MEN1KMT2ARAB9A | |
| SCHEMBL7463048 | 0.81 | CYP3A4 (0.57) | ROCK1ROCK2MEN1KMT2ARAB9A | |
| SCHEMBL7473115 | 0.73 | LTA4H (0.46) | ROCK1ROCK2MEN1KMT2ARAB9A | |
| SCHEMBL7473110 | 0.73 | LTA4H (0.46) | ROCK1ROCK2MEN1KMT2ARAB9A | |
| SCHEMBL27601320 | 0.72 | MEN1 (0.48) | MEN1KMT2ARAB9AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6174792 | 0.72 | MEN1 (0.48) | MEN1KMT2ARAB9AALDH1A1MAPT | |
| SCHEMBL14825155 | 0.70 | RAB9A (0.75) | MEN1KMT2ARAB9AALDH1A1MAPT | |
| SCHEMBL7478638 | 0.70 | MEN1 (0.50) | ROCK1ROCK2MEN1KMT2ARAB9A | |
| SCHEMBL18114095 | 0.69 | MEN1 (0.74) | MEN1KMT2ARAB9AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6173338 | 0.68 | RAB9A (0.50) | ROCK1MEN1KMT2ARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| US-20260103471-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4701627-A1 | ORAL PHARMACEUTICAL COMPOSITIONS | Assembly Biosciences, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260042766-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260042767-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014154-A1 | CYCLIC UREA THIAZOLYL COMPOUND FOR TREATMENT OF VIRAL INFECTIONS UNRESPONSIVE TO TREATMENT WITH A FIRST ANTIVIRAL THERAPY | ASSEMBLY BIOSCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250376478-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250339502-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4581029-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024049760-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024047508-A1 | PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023161427-A1 | VIRAL COMBINATION THERAPY | EISBACH BIO GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| US-20230147602-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-113384588-B | Application of mifepristone in preparation of anti-porcine pseudorabies virus drugs | 南京农业大学 | 2022-03-08 | — | — | CN | disclosed |
| WO-2021188866-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188974-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | ROCK1 4385/4885ROCK2 3988/4885MEN1 74/4885 |
| US-20260103471-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | TK1, UNG, SMCHD1 | ROCK1 4743/4885ROCK2 4658/4885MEN1 897/4885 |
| US-20260014154-A1 | CYCLIC UREA THIAZOLYL COMPOUND FOR TREATMENT OF VIRAL INFECTIONS UNRESPONSIVE TO TREATMENT WITH A FIRST ANTIVIRAL THERAPY | DNA2, TK1, TYMP | ROCK1 4129/4885ROCK2 3902/4885MEN1 3889/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | ROCK1 4385/4885ROCK2 3988/4885MEN1 74/4885 |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | CXCR1, ZC3HAV1L, ZC3HAV1 | ROCK1 2446/4885ROCK2 2539/4885MEN1 4347/4885 |
| US-20260042767-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF HSV | HVCN1, CACNA1S, HCN1 | ROCK1 3025/4885ROCK2 3674/4885MEN1 3610/4885 |
| US-20250376478-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | TYMP, TK1, TREH | ROCK1 3956/4885ROCK2 4151/4885MEN1 3093/4885 |
| US-20260042766-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF HSV | HVCN1, CACNA1S, HCN1 | ROCK1 2651/4885ROCK2 3330/4885MEN1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.